Evaluating the Role of CXCR3 in Pain Modulation: A Literature Review

References

• Julius D. TRP channels and pain. Annu Rev Cell Dev Biol. 2013;29(1):355–384. doi:10.1146/annurev-cellbio-101011-155833
   PubMed Web of Science ®Google Scholar
• White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(51):20151–20158. doi:10.1073/pnas.0709250104
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–284. doi:10.1016/j.cell.2009.09.028
   PubMed Web of Science ®Google Scholar
• Kalyuzhny AE, Arvidsson U, Wu W, Wessendorf MW. μ-Opioid and δ-opioid receptors are expressed in brainstem antinociceptive circuits: studies using immunocytochemistry and retrograde tract-tracing. J Neurosci. 1996;16(20):6490–6503. doi:10.1523/JNEUROSCI.16-20-06490.1996
   Web of Science ®Google Scholar
• Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia—when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019;393(10180):1558–1568. doi:10.1016/S0140-6736(19)30430-1
   PubMed Web of Science ®Google Scholar
• Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions. Pain. 1995;62(3):259–274. doi:10.1016/0304-3959(95)00073-2
   PubMed Web of Science ®Google Scholar
• Verma V, Sheikh Z, Ahmed AS. Nociception and role of immune system in pain. Acta Neurol Belg. 2015;115(3):213–220. doi:10.1007/s13760-014-0411-y
   Web of Science ®Google Scholar
• Qin L, Kufareva I, Holden LG, et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science. 2015;347(6226):1117–1122. doi:10.1126/science.1261064
   PubMed Web of Science ®Google Scholar
• Raucci R, Colonna G, Giovane A, Castello G, Costantini S. N-terminal region of human chemokine receptor CXCR3: structural analysis of CXCR3 (1–48) by experimental and computational studies. Biochim Biophys Acta Bioenerg. 2014;1844(10):1868–1880. doi:10.1016/j.bbapap.2014.08.004
   Web of Science ®Google Scholar
• Burg JS, Ingram JR, Venkatakrishnan A, et al. Structural basis for chemokine recognition and activation of a viral G protein–coupled receptor. Science. 2015;347(6226):1113–1117. doi:10.1126/science.aaa5026
   Web of Science ®Google Scholar
• Nguyen AF. Purification and Study of CC Chemokine-Based Strategies to Combat Chronic Inflammation and HIV. UC Merced; 2017.
   Google Scholar
• Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, Van Den Berg WB. The role of synovial macrophages and macrophage‐produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010;62(3):647–657. doi:10.1002/art.27290
   PubMed Web of Science ®Google Scholar
• Breser ML, Motrich RD, Sanchez LR, Mackern-Oberti JP, Rivero VE. Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome. J Immunol. 2013;190(7):3121–3133. doi:10.4049/jimmunol.1202482
   PubMed Web of Science ®Google Scholar
• Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184(3):963–969. doi:10.1084/jem.184.3.963
   PubMed Web of Science ®Google Scholar
• Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101(4):746–754. doi:10.1172/jci1422
   PubMed Web of Science ®Google Scholar
• Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, Inflammation, and autoimmune diseases. Contemp Challenge Autoimmun. 2009;1173:310. doi:10.1111/j.1749-6632.2009.04813.x
   Web of Science ®Google Scholar
• Liu Q-Z, Ma W-T, Yang J-B, et al. The CXC chemokine receptor 3 inhibits autoimmune cholangitis via CD8+ T cells but promotes colitis via CD4+ T cells. Front Immunol. 2018;9:1090. doi:10.3389/fimmu.2018.01090
   Web of Science ®Google Scholar
• Chen W, Ukah TK, Miller MM, Zaghouani H, Wan X. PI3K-AKT-mTOR pathway mediates trafficking of diabetogenic T cells by modulating CXCR3 via T-bet. Am Assoc Immunol. 2016.
   Google Scholar
• Oghumu S, Stock JC, Varikuti S, et al. Transgenic expression of CXCR3 on T cells enhances susceptibility to cutaneous Leishmania major infection by inhibiting monocyte maturation and promoting a Th2 response. Infect Immun. 2015;83(1):67–76. doi:10.1128/IAI.02540-14
   Web of Science ®Google Scholar
• Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197(11):1537–1549. doi:10.1084/jem.20021897
   PubMed Web of Science ®Google Scholar
• Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol. 2004;173(10):6234–6240. doi:10.4049/jimmunol.173.10.6234
   Web of Science ®Google Scholar
• Smith HS. Current Therapy in Pain: 1st ed. Philadelphia: Saunders. Elsevier Health Sciences. 2009.
   Google Scholar
• Rappert A, Biber K, Nolte C, et al. Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl− current and chemotaxis in murine microglia. J Immunol. 2002;168(7):3221–3226. doi:10.4049/jimmunol.168.7.3221
   Web of Science ®Google Scholar
• Bhangoo S, Ren D, Miller RJ, et al. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain. 2007;3:1744–8069-3-38. doi:10.1186/1744-8069-3-38
   Web of Science ®Google Scholar
• Qu L, Fu K, Yang J, Shimada SG, LaMotte RH. CXCR3 chemokine receptor signaling mediates itch in experimental allergic contact dermatitis. Pain. 2015;156(9):1737. doi:10.1097/j.pain.0000000000000208
   PubMed Web of Science ®Google Scholar
• Van den Beuken-van Everdingen M, De Rijke J, Kessels A, Schouten H, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449. doi:10.1093/annonc/mdm056
   PubMed Web of Science ®Google Scholar
• Terricabras E, Benjamim C, Godessart N. Drug discovery and chemokine receptor antagonists: eppur si muove! Autoimmun Rev. 2004;3(7–8):550–556. doi:10.1016/j.autrev.2004.07.037
   Web of Science ®Google Scholar
• Rahman I. Functional Analysis of the G-Protein Coupled Chemokine Receptor CXCR3-A and Its Ligands. University of Reading; 2007.
   Google Scholar
• Chow E, Ding K, Parulekar WR, et al. Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiother Oncol. 2016;118(3):547–551. doi:10.1016/j.radonc.2015.10.018
   Web of Science ®Google Scholar
• Guan X-H, Fu Q-C, Shi D, et al. Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp Neurol. 2015;263:39–49. doi:10.1016/j.expneurol.2014.09.019
   PubMed Web of Science ®Google Scholar
• Guo G, Gao F. CXCR3: latest evidence for the involvement of chemokine signaling in bone cancer pain. Exp Neurol. 2015;265:176–179. doi:10.1016/j.expneurol.2015.02.003
   Web of Science ®Google Scholar
• Bu H, Shu B, Gao F, et al. Spinal IFN-γ-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. Breast Cancer Res Treat. 2014;143(2):255–263. doi:10.1007/s10549-013-2807-4
   PubMed Web of Science ®Google Scholar
• Zhou Y-Q, Gao H-Y, Guan X-H, et al. Chemokines and their receptors: potential therapeutic targets for bone cancer pain. Curr Pharm Des. 2015;21(34):5029–5033. doi:10.2174/1381612821666150831141931
   PubMed Web of Science ®Google Scholar
• Zhou YQ, Liu DQ, Chen SP, et al. The role of CXCR3 in neurological diseases. Curr Neuropharmacol. 2019;17(2):142–150. doi:10.2174/1570159X15666171109161140
   Web of Science ®Google Scholar
• Chen Y, Yin D, Fan B, et al. Chemokine CXCL10/CXCR3 signaling contributes to neuropathic pain in spinal cord and dorsal root ganglia after chronic constriction injury in rats. Neurosci Lett. 2019;694:20–28. doi:10.1016/j.neulet.2018.11.021
   Web of Science ®Google Scholar
• Jiang B-C, He L-N, Wu X-B, et al. Promoted interaction of C/EBPα with demethylated Cxcr3 gene promoter contributes to neuropathic pain in mice. J Neurosci. 2017;37(3):685–700. doi:10.1523/JNEUROSCI.2262-16.2016
   Web of Science ®Google Scholar
• Wang C, Li Q, Jia Z, et al. Spinal caspase-6 contributes to remifentanil-induced hyperalgesia via regulating CCL21/CXCR3 pathway in rats. Neurosci Lett. 2020;721:134802. doi:10.1016/j.neulet.2020.134802
   Web of Science ®Google Scholar
• Burguillos MA, Deierborg T, Kavanagh E, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011;472(7343):319–324. doi:10.1038/nature09788
   PubMed Web of Science ®Google Scholar
• Xu W, Liu W, Yu W. The involvement of iron responsive element (-) divalent metal transporter 1-mediated the spinal iron overload via CXCL10/CXCR3 pathway in neuropathic pain in rats. Neurosci Lett. 2019;694:154–160. doi:10.1016/j.neulet.2018.12.001
   Web of Science ®Google Scholar
• Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis. 2009;16(4):879–895. doi:10.3233/JAD-2009-1010
   PubMed Web of Science ®Google Scholar
• Ingrassia R, Garavaglia B, Memo M. DMT1 expression and iron levels at the crossroads between aging and neurodegeneration. Front Neurosci. 2019;13(575). doi:10.3389/fnins.2019.00575
   Web of Science ®Google Scholar
• Shu RC, Zhang LL, Wang CY, et al. Spinal peroxynitrite contributes to remifentanil-induced postoperative hyperalgesia via enhancement of divalent metal transporter 1 without iron-responsive element–mediated iron accumulation in rats. Anesthesiology. 2015;122(4):908–920. doi:10.1097/ALN.0000000000000562
   Web of Science ®Google Scholar
• Jing P-B, Cao D-L, Li -S-S, et al. Chemokine receptor CXCR3 in the spinal cord contributes to chronic itch in mice. Neurosci Bull. 2018;34(1):54–63. doi:10.1007/s12264-017-0128-z
   Web of Science ®Google Scholar
• Piotrowska A, Rojewska E, Pawlik K, et al. Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness-evidence from in vivo and in vitro studies. Biochim Biophys Acta Biomembr. 2018;1864(10):3418–3437. doi:10.1016/j.bbadis.2018.07.032
   Web of Science ®Google Scholar
• Piotrowska A, Rojewska E, Pawlik K, et al. Dataset of (±)-NBI-74330 (CXCR3 antagonist) influence on chemokines under neuropathic pain. Data Brief. 2018;21:1145–1150. doi:10.1016/j.dib.2018.10.091
   Web of Science ®Google Scholar
• Wang W, Peng Y, Yang H, et al. Potential role of CXCL10/CXCR3 signaling in the development of morphine tolerance in periaqueductal gray. Neuropeptides. 2017;65:120–127. doi:10.1016/j.npep.2017.07.004
   Web of Science ®Google Scholar
• Bajova H, Nelson TE, Gruol DL. Chronic CXCL10 alters the level of activated ERK1/2 and transcriptional factors CREB and NF-κB in hippocampal neuronal cell culture. J Neuroimmunol. 2008;195(1–2):36–46. doi:10.1016/j.jneuroim.2008.01.003
   PubMed Web of Science ®Google Scholar
• Wang A, Bibb JA. Is CREB the angry bird that releases memory in alzheimer’s? Neuropsychopharmacology. 2011;36(11):2153–2154. doi:10.1038/npp.2011.126
   Web of Science ®Google Scholar
• Li HL, Huang Y, Zhou YL, et al. CXC motif chemokine 10 contributes to the development of neuropathic pain by increasing the permeability of the blood–spinal cord barrier. Front Immunol. 2020;11:477. doi:10.3389/fimmu.2020.00477
   Web of Science ®Google Scholar
• Ye D, Bu H, Guo G, et al. Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein. J Mol Neurosci. 2014;53(4):571–579. doi:10.1007/s12031-013-0223-1
   PubMed Web of Science ®Google Scholar
• Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823–836. doi:10.1038/nrn2947
   PubMed Web of Science ®Google Scholar
• Lurati A, Laria A, Gatti A, Brando B, Scarpellini M. Different T cells’ distribution and activation degree of Th17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis, and healthy donors: preliminary results of the MAGENTA CLICAO study. Open Access Rheumatol. 2015;7:63. doi:10.2147/OARRR.S81905
   PubMedGoogle Scholar
• Miller RE, Miller RJ, Malfait A-M. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014;70(2):185–193. doi:10.1016/j.cyto.2014.06.019
   PubMed Web of Science ®Google Scholar
• Penatti A, Facciotti F, De Matteis R, et al. Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):103. doi:10.1186/s13075-017-1305-1
   Web of Science ®Google Scholar
• Jenh C-H, Cox MA, Cui L, et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012;13(1):1–14. doi:10.1186/1471-2172-13-2
   Web of Science ®Google Scholar
• Benigni G, Dimitrova P, Antonangeli F, et al. CXCR3/CXCL10 axis regulates neutrophil–NK cell cross-talk determining the severity of experimental osteoarthritis. J Immunol. 2017;198(5):2115–2124. doi:10.4049/jimmunol.1601359
   Web of Science ®Google Scholar
• Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120(11):3779–3787. doi:10.1172/JCI43766
   PubMed Web of Science ®Google Scholar
• Heinricher M, Morgan M, Tortorici V, Fields H. Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience. 1994;63(1):279–288. doi:10.1016/0306-4522(94)90022-1
   PubMed Web of Science ®Google Scholar
• Carr FB, Géranten SM, Hunt SP. Descending controls modulate inflammatory joint pain and regulate CXC chemokine and iNOS expression in the dorsal horn. Mol Pain. 2014;10:1744–8069-10-39. doi:10.1186/1744-8069-10-39
   Web of Science ®Google Scholar
• Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB, Yoshimura N. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opin Emerg Drugs. 2015;20(4):555–570. doi:10.1517/14728214.2015.1105216
   PubMed Web of Science ®Google Scholar
• Silva T, Garlet GP, Fukada SY, JSd S, Cunha F. Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res. 2007;86(4):306–319. doi:10.1177/154405910708600403
   Web of Science ®Google Scholar
• Kim H-J. Update on the pathology and diagnosis of interstitial cystitis/bladder pain syndrome: a review. Int Neurourol J. 2016;20(1):13. doi:10.5213/inj.1632522.261
   Web of Science ®Google Scholar
• Akiyama Y, Morikawa T, Maeda D, et al. Increased CXCR3 expression of infiltrating plasma cells in Hunner type interstitial cystitis. Sci Rep. 2016;6(1):1–7. doi:10.1038/srep28652
   Web of Science ®Google Scholar
• Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2014;64(1):57–80. doi:10.1111/prd.12002
   PubMed Web of Science ®Google Scholar
• Meyle J, Chapple I. Molecular aspects of the pathogenesis of periodontitis. Periodontol 2000. 2015;69(1):7–17. doi:10.1111/prd.12104
   PubMed Web of Science ®Google Scholar
• Hiyari S, Green E, Pan C, et al. Genomewide association study identifies Cxcl family members as partial mediators of LPS‐induced periodontitis. J Bone Miner Res. 2018;33(8):1450–1463. doi:10.1002/jbmr.3440
   Web of Science ®Google Scholar
• Hosokawa Y, Hosokawa I, Ozaki K, Nakanishi T, Nakae H, Matsuo T. Catechins inhibit CCL20 production in IL-17A-stimulated human gingival fibroblasts. Cell Physiol Biochem. 2009;24(5–6):391–396. doi:10.1159/000257431
   Google Scholar
• Garlet GP, Avila-Campos MJ, Milanezi CM, Ferreira BR, Silva JS. Actinobacillus actinomycetemcomitans-induced periodontal disease in mice: patterns of cytokine, chemokine, and chemokine receptor expression and leukocyte migration. Microbes Infect. 2005;7(4):738–747. doi:10.1016/j.micinf.2005.01.012
   PubMed Web of Science ®Google Scholar
• Adachi T, Nakanishi T, Yumoto H, et al. Caries-related bacteria and cytokines induce CXCL10 in dental pulp. J Dent Res. 2007;86(12):1217–1222. doi:10.1177/154405910708601215
   Web of Science ®Google Scholar
• Horst OV, Horst JA, Samudrala R, Dale BA. Caries induced cytokine network in the odontoblast layer of human teeth. BMC Immunol. 2011;12(1):9. doi:10.1186/1471-2172-12-9
   PubMed Web of Science ®Google Scholar